ArticleNeuropharmacology2026
Disruption of dopamine transmission by cholesterol depletion is associated with alterations in protein lipid raft partitioning and actin dynamics.
Article in Neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Disrupted brain cholesterol homeostasis is implicated in neurological disorders involving aberrant dopamine (DA) signaling; however, the direct effects of cholesterol on DA transmission in native tissue have not yet been demonstrated. Using ex vivo fast-scan cyclic voltammetry in nucleus accumbens slices from male rats, we found that membrane cholesterol depletion with methyl-β-cyclodextrin (MβCD, 3-10 mM) significantly reduced evoked DA release and decreased the apparent maximal rate of DA reuptake via the dopamine transporter (DAT). Because cholesterol is critical for the formation of lipid raft microdomains, cholesterol depletion could disrupt DA transmission by altering the membrane localization of proteins involved in neurotransmitter release. Using sucrose density gradient fractionation, we found that MβCD decreased the raft association of vesicle-associated membrane protein 2 (VAMP2) without altering the localization of syntaxin-1A, synaptosomal-associated protein 25, synaptotagmin-1, and N-type voltage-gated calcium channels. Therefore, MβCD may reduce DA release by disrupting localization of VAMP2, a core component of the vesicle fusion machinery. We also examined actin polymerization, a key regulator of vesicle docking and fusion, and found that MβCD treatment decreased actin polymerization, as evidenced by an increased globular-to-filamentous actin ratio and reduced phalloidin labeling of filamentous actin in striatal slices. Finally, although DAT lipid raft localization was unchanged, MβCD attenuated cocaine's ability to inhibit DAT reuptake function, suggesting that cholesterol depletion disrupts the outward-facing conformation of DAT required for high-affinity ligand binding. Overall, these findings provide new mechanistic insights into how cholesterol depletion may contribute to dysregulated DA signaling in diseases involving altered brain cholesterol metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.